Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 6:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 21,991 matching trials from the live ClinicalTrials.gov search.

Filters: Recruiting Clear all

Conditions: Pregnancy
Interventions: Vitamin D dynamics-pregnant, Vitamin D dynamics-nonpregnant; Other
Lead sponsor: Cornell University; Other
Eligibility: 20 Years to 39 Years · Female only
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Tobacco Use
Interventions: Semaglutide, Placebo; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Alcohol Use Disorder
Interventions: CMND-100; Drug
Lead sponsor: Clearmind Medicine Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: New Haven, Connecticut • Baltimore, Maryland

Conditions: Multiple Myeloma
Interventions: Non-Interventional Study; Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 11
States / cities: Goodyear, Arizona • Duarte, California • Huntington Beach, California + 8 more

Conditions: Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Serous Adenocarcinoma, Malignant Uterine Neoplasm, Uterine Corpus Carcinosarcoma
Interventions: Biospecimen Collection, Liquid Biopsy, Pap Smear; Procedure · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Knee Osteoarthritis
Interventions: ROAM OA Single Upright Knee Brace, Ossur Unloader One Knee Brace or Standard of Care; Device
Lead sponsor: Rush University Medical Center; Other
Eligibility: 40 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Neuromuscular Diseases
Interventions: ActivPal; Other
Lead sponsor: Columbia University; Other
Eligibility: 1 Year and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: HTLV-I Infection, Tropical Spastic Paraparesis
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 750 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 1998
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Food Addiction
Interventions: Low UP (meals provided), Low UP (self-guided), Active Control; Other
Lead sponsor: University of Michigan; Other
Eligibility: 22 Years to 60 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Colorectal Cancer
Interventions: Fruquintinib; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 44
States / cities: Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 34 more

Conditions: Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Sensation Disorders, Vision Disorder, Neurological Manifestations, Eye Diseases, Hereditary, Eye Diseases, Eye Disorders Congenital, Retinal Disease
Interventions: sepofarsen, Placebo IVT; Drug · Other
Lead sponsor: Laboratoires Thea; Industry
Eligibility: 6 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: San Francisco, California • Miami, Florida • Iowa City, Iowa + 2 more

Conditions: Multiple Sclerosis, Control Subjects, Autonomic Dysreflexia
Interventions: Tests of sympathetic inhibition, Tests of sympathetic activation, Testing of autonomic dysreflexia; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 50 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy Volunteer
Interventions: Not listed
Lead sponsor: National Institute on Deafness and Other Communication Disorders (NIDCD); NIH
Eligibility: 5 Years to 80 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Carcinoma in the Liver
Interventions: Biopsy, Biospecimen Collection, Cemiplimab, Computed Tomography, Magnetic Resonance Imaging, Transarterial Radioembolization, Yttrium Y 90 Resin Microspheres; Procedure · Biological · Radiation
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Message Exposure (Sequence: Regular Then Flavor), Message Exposure (Sequence: Flavor Then Regular), No Message Exposure (Control Condition)
Interventions: Exposure to Anti-Vaping Messages (generic themes then flavor-specific themes), Exposure to Anti-Vaping Messages (flavor-specific themes then generic themes), Exposure to Anti-Vaping Messages (no message exposure); Behavioral
Lead sponsor: University of Georgia; Other
Eligibility: 18 Years to 29 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Athens, Georgia

Conditions: Juxtarenal Aortic Aneurysm, Pararenal Aneurysm, Thoracoabdominal Aortic Aneurysm
Interventions: Cook Alpha TX2 Stent Graft, Cook Zenith TX2, and Cook Zenith Fenestrated Stent Graft; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Bladder Cancer
Interventions: Stent placement, Alvimopan; Procedure · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Liver Metastases, Stereotactic Body Radiation Therapy, MRI-guided Treatment
Interventions: SBRT; Radiation
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Bleeding, Clot Blood
Interventions: Aspirin, Warfarin; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Chicago, Illinois • New York, New York • Houston, Texas

Conditions: Insomnia, PTSD - Post Traumatic Stress Disorder, Nightmares
Interventions: Cognitive-Behavioral Therapy for Insomnia (CBTi), Cognitive Behavioral Therapy for Nightmares (CBTn), Written Exposure Therapy (WET), Sleep Hygiene; Behavioral
Lead sponsor: Palo Alto Veterans Institute for Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Kileen, Texas

Conditions: Alzheimer Dementia, Dementia, Alzheimer Dementia (AD), Alzheimer, Alzheimer s Disease
Interventions: Low Dose Radiation Therapy; Radiation
Lead sponsor: Evan Thomas; Other
Eligibility: 50 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Winter Park, Florida

Conditions: Type 2 Diabetes
Interventions: Continuous Glucose Monitoring Academy, Standard Education; Behavioral
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 8 Years to 21 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Advanced Solid Tumor, Metastatic Solid Tumor
Interventions: DS-3939a; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 12
States / cities: Sarasota, Florida • Locust Grove, Georgia • Westwood, Kansas + 9 more

Conditions: Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma
Interventions: Biopsy, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Glofitamab, Lenalidomide, Obinutuzumab, Positron Emission Tomography, Venetoclax; Procedure · Biological · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Duarte, California • New York, New York • Salt Lake City, Utah

Search by objective public record fields.

Vitamin D Dynamics in Women

Impact of Semaglutide on Tobacco Use and Related Health Behaviors

A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Subjects

A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients

Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers

ROAM OA: Functional and Patient Reported Outcomes Wearing a Knee Brace for Unicompartmental OA

Measuring Physical Activity With ActivPal

Evaluation of Patients With HAM/TSP

Ultra Crave: An Investigation of Ultra-Processed Food

A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)

Deciphering Preserved Autonomic Function After Multiple Sclerosis

Normal Values in Hearing and Balance Testing

Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer

Neuroimaging Approaches to Improve Prediction of Smoking Initiation and Nicotine Escalation in Young Adult ENDS Users

Clinical Outcomes and Major Adverse Events in Patients Treated With Physician-Modified Fenestrated and Branched Stent Grafts

A Study of Surgical Techniques During Cystectomy

OAR-Based, Dose Escalated SBRT With Real Time Adaptive MRI Guidance for Liver Metastases

Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients With Assist Device

Accelerated Treatment for Co-occurring Insomnia, Nightmares, and PTSD

Low-Dose Radiotherapy for Alzheimer's Disease

Type 2 Continuous Glucose Monitoring Academy

First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma